Mandate

VINGE ADVISES INDUSTRIFONDEN IN CONNECTION WITH THE FINANCING OF HASSELBLAD’S NEW CAMERAS

December 11, 2013

Industrifonden has provided financing to the camera maker, Hasselblad, in the form of a loan of approximately SEK 78 million with detachable options. The funds will be used for the launch of Hasselblad’s new series of cameras and for renewal of the existing range of cameras.

The new cameras will be available on the market shortly and the first two models, i.e. Lunar and Stellar, were launched recently. Since they are intended for amateur photographers, they are in a lower price and performance segment compared to Hasselblad’s traditional range of products, which are directed toward professional photographers.

Hasselblad’s current owner, the German-Swiss private equity firm, Vorndran Mannheims Capital, has made significant contributions in the form of renewal and greater degree of frequency of change of models in the existing H-system, where H5D was launched at the beginning of 2013.

Hasselblad’s production and R&D divisions are now based in Gothenburg where the company has doubled its production capacity and has recruited new personnel. Hasselblad is thus once again primarily a Swedish company.

Vinge’s team consisted of partner Johan Larsson and associate Lisa Antman.   

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025